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Abstract
Background: Chronic Kidney Disease is a major cause of morbidity and interventions now exist which can reduce risk. 
We sought to develop and validate two new risk algorithms (the QKidney® Scores) for estimating (a) the individual 5 
year risk of moderate-severe CKD and (b) the individual 5 year risk of developing End Stage Kidney Failure in a primary 
care population.
Methods: We conducted a prospective open cohort study using data from 368 QResearch® general practices to 
develop the scores. We validated the scores using two separate sets of practices - 188 separate QResearch® practices 
and 364 practices contributing to the THIN database.
We studied 775,091 women and 799,658 men aged 35-74 years in the QResearch® derivation cohort, who contributed
4,068,643 and 4,121,926 person-years of observation respectively.
We had two main outcomes (a) moderate-severe CKD (defined as the first evidence of CKD based on the earliest of any
of the following: kidney transplant; kidney dialysis; diagnosis of nephropathy; persistent proteinuria; or glomerular
filtration rate of < 45 mL/min) and (b) End Stage Kidney Failure.
We derived separate risk equations for men and women. We calculated measures of calibration and discrimination
using the two separate validation cohorts.
Results: Our final model for moderate-severe CKD included: age, ethnicity, deprivation, smoking, BMI, systolic blood 
pressure, diabetes, rheumatoid arthritis, cardiovascular disease, treated hypertension, congestive cardiac failure; 
peripheral vascular disease, NSAID use and family history of kidney disease. In addition, it included SLE and kidney 
stones in women. The final model for End Stage Kidney Failure was similar except it did not include NSAID use.
Each risk prediction algorithms performed well across all measures in both validation cohorts. For the THIN cohort, the
model to predict moderate-severe CKD explained 56.38% of the total variation in women and 57.49% for men. The D
statistic values were high with values of 2.33 for women and 2.38 for men. The ROC statistic was 0.875 for women and
0.876 for men.
Conclusions: These new algorithms have the potential to identify high risk patients who might benefit from more 
detailed assessment, closer monitoring or interventions to reduce their risk.
Background
Chronic Kidney Disease (CKD) is a significant cause of
morbidity and mortality across the developed world. It is
associated with increased risk of death from cardiovascu-
lar disease[1-3], as well as from End Stage Kidney Fail-
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ure[3]. The health burden due to CKD is likely to
continue to rise with the ageing population and world-
wide increase in Type 2 Diabetes[4]. CKD is an insidious
disease characterised by a clear natural history with a
detectable asymptomatic period during which interven-
tions (such as blood pressure control) could help prevent
or delay progression to End Stage Kidney Failure[5].
Despite this, patients are often identified and referred late
when up to half already require Kidney dialysis or trans-
plantation[6,7].
Whilst there are no randomised trials demonstrating
that screening for CKD improves clinical outcomes,
national programmes recommend that individuals who
are at increased risk of CKD are tested for undetected
kidney disease[8,9]. Reliable methods for identification of
high risk patients are likely to be needed to identify and
target early assessment and interventions to maximise
health gain and improve outcomes[4].
High quality representative data within electronic
patient records from primary care can be used to derive
and validate robust risk prediction algorithms which can
be then implemented and evaluated in clinical settings.
This has already been achieved with the cardiovascular
risk algorithm QRISK®2[10] which is integrated into the
EMIS Clinic Computer System used by over half of gen-
eral practices in the UK. The approach is being extended
to other clinical conditions[11,12].
Although the case for developing a risk prediction
model for CKD has been articulated[13], there are cur-
rently no widely accepted algorithms available to predict
risk of CKD for an individual patient within primary care.
In this paper, we describe the derivation and validation of
two new risk predictions algorithms to predict 5 year risk
of moderate-severe kidney disease. Designed to integrate
with QRISK®2[10] and the QDScore®[12] for diabetes, the
QKidney® Scores complete the triad of prediction algo-
rithms developed to identify patients at high risk of vas-
cular disease for intervention.
Methods
Study design and sample
We did a prospective open cohort study in a large popula-
tion of primary care patients using the QResearch® data-
base (version 22). We included all practices in England
and Wales who had been using their EMIS computer sys-
tem for at least a year. We used established methods for
the study design and analysis which we summarise here
and which are described and reviewed in detail else-
where[10-12,14-16].
We randomly allocated two thirds of practices to the
derivation cohort and the remaining third to a validation
cohort. We identified an open cohort of patients aged 35-
74 years without recorded evidence of CKD at study
entry, registered with practices between the study start
date of 01 Jan 2002 and the study end date of 31 Dec 2008.
Patients entered the study on the latest of study start date,
date of first registration with the practice or date they
became 35 years old. Patients were censored at the earli-
est date of development of CKD, death, de-registration
with the practice, last upload of computerised data or the
study end date. Patients could therefore have up to 7
years of follow up data available.
We used the same inclusion and exclusion criteria to
i d e n t i f y  a  s e p a r a t e  s a m p l e  o f  p a t i e n t s  d r a w n  f r o m  a n
independent set of practices contributing to the THIN
primary care research database http://www.thin-uk.com
except the study end date for this sample was 30 June
2008.
Definition of Outcomes
We had two main outcomes. One outcome was recorded
evidence of moderate-severe CKD defined as the first
occurrence of any of the following during follow-up:
a) recorded kidney transplant;
b) recorded kidney dialysis;
c) recorded diagnosis of nephropathy;
d) glomerular filtration rate < 45 mL/min/1.73m2 cor-
responding to stage 3B CKD[9].
e) recorded diagnosis of proteinuria;
Our second main outcome was End Stage Kidney Fail-
ure which was defined as the first occurrence of any of
the following during follow-up:
a) recorded kidney transplant;
b) recorded kidney dialysis;
c) glomerular filtration rate < 15 mL/min/1.73m2 cor-
responding to stage 5 CKD[9].
We calculated the glomerular filtration rates using the
MDRD equation[17] using laboratory reported creatinine
values
Predictor variables
We developed models for men and women for each of
our two main outcomes. Our initial list of predictor vari-
ables included those known to be associated with
increased risk of CKD based on the literature[1,2,5,18,19]
and from national guidance[9] which are also likely to be
recorded in the patients electronic health record. We also
sought the opinions of two senior nephrologists including
the National Clinical Director for Kidney Services in Eng-
land, Dr Donal O'Donoghue.
Variables examined for inclusion in both models were:
• Age at study entry (in single years)
• Body mass index
• Systolic blood pressure (mmHg)
• Smoking status (non-smoker, ex-smoker; light 
smoker: < 10 cigarettes/day, moderate smoker: 10-19 
cigarettes per day, heavy smoker: 20 or more ciga-
rettes per day)Hippisley-Cox and Coupland BMC Family Practice 2010, 11:49
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• Ethnic group
• Townsend deprivation score (derived from the 
patient's postcode) [20]
• Diagnosis of type 1 diabetes
• Diagnosis of type 2 diabetes
• Diagnosis of cardiovascular disease
• Diagnosis of rheumatoid arthritis
• Treated hypertension
• Diagnosis of congestive cardiac failure
• Diagnosis of peripheral vascular disease
• Diagnosis of systemic lupus erythematosis
• Two or more prescriptions for NSAIDs drugs in the 
6 months before study entry
• Evidence of kidney stones based on diagnosis or 
operative procedure at baseline
• Recorded family history of kidney disease including 
polycystic kidneys
• Prostatic hypertrophy at baseline (men)
In both models we only used diagnoses recorded prior
to the baseline date as predictor variables, for body mass
index, smoking status and systolic blood pressure we
used the values recorded closest to the study entry date.
Ethnic group was categorised as in previous publica-
tions[10].
Statistical analysis
We developed and validated the risk prediction algo-
rithms using established methods described in detail
elsewhere [10-12,14-16]. In summary, we used Cox's pro-
portional hazards models to estimate the coefficients for
each risk factor for both outcomes for men and women
separately, adjusting for other baseline risk factors. We
excluded patients with the outcome at baseline. We used
fractional polynomials to model non-linear risk relation-
ships with continuous variables[21]. We compared mod-
els using the Akaike information criterion (AIC). We
used multiple imputation to replace missing values for
body mass index, systolic blood pressure and smoking
status and used these values in our main analyses[22-25].
We carried out 5 imputations. We examined interactions
between predictor variables and age, and we included sig-
nificant variables and significant interaction terms in the
final models. We took the regression coefficients for each
variable from the final models and used these as weights
which we combined with the baseline survivor function
for moderate-severe CKD evaluated at 5 years to derive
risk equations for (a) moderate-severe CKD and (b) End
Stage Kidney Failure at 5 years' follow-up.
We applied the algorithms obtained from the deriva-
tion cohort to both validation cohorts and calculated
measures of discrimination (D statistic[26] , R 2 statistic
for survival data and area under the receiver operating
characteristic curve (ROC statistic)) and calibration
(comparing observed with predicted risks by tenth of pre-
dicted risk). We used the THIN validation sample for our
main validation as this is from practices using a different
clinical computer system from QResearch practices. We
used all the available data on each database to maximise
the power and also generalisability of the results. We used
STATA (version 11) for all analyses.
The project has been independently reviewed in accor-
dance with the QResearch® agreement with Trent Multi-
Centre Research Ethics Committee.
Results
Study population
Overall, 556 QResearch® practices in England and Wales
met our inclusion criteria, of which 368 were randomly
assigned to the derivation dataset and 188 to the QRe-
search® validation dataset.
In the QResearch®  derivation cohort there were
1,591,884 patients aged 35 to 74 at baseline of whom
17,135 had recorded evidence of pre-existing CKD and
were therefore excluded leaving 1,574,749 patients for
analysis. Of those with pre-existing CKD, 1,266 women
and 1,524 men had End Stage Kidney Failure. In the QRe-
search®  validation cohort there were 796,598 patients
aged 35 to 74 at baseline of whom 8,278 had recorded evi-
dence of CKD at baseline leaving 788,320 for analysis.
There were 364 practices from the THIN database
which met our inclusion criteria. The THIN cohort con-
sisted of 1,595,141 patients aged 35 to 74 of whom 13,396
had recorded evidence of CKD at baseline leaving
1,581,745 for analysis.
Baseline characteristics for both the THIN and QRe-
search® validation cohorts were very similar to the QRe-
search® derivation cohort in both men and women as
shown in Table 1.
Missing data
Table 1 also shows the proportions of patients with values
recorded for smoking status, body mass index, systolic
blood pressure and serum creatinine. Complete data for
smoking status, body mass index and systolic blood pres-
sure were available for 77.15% of patients in the QRe-
search derivation cohort and 77.57% of patients in the
THIN validation cohort. There were differences in
observed characteristics between those with and without
missing data. As in previous studies[12,27], this pattern
of missing data supports the use of multiple imputation
(results available from the authors) under the assumption
that data are missing at random.
Incidence rates for both outcomes
Table 2 shows the age/sex incidence rates of moderate-
severe CKD and Table 3 shows the incidence rates for
End Stage Kidney Failure in both the QResearch® deriva-
tion cohort and the THIN validation cohort.Hippisley-Cox and Coupland BMC Family Practice 2010, 11:49
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During the 4,068,643 person years of follow up for
women in the derivation cohort without moderate-severe
CKD at baseline, there were 23,786 incident cases of
moderate-severe CKD giving an overall incidence rate of
58.46 per 10,000 person years. For men, there were
17,333 moderate-severe CKD cases arising from
4,121,926 person years giving a crude incidence rate of
42.05 per 10,000 person years. During the 4,177,287 per-
son years of follow up for women in the derivation cohort
without End Stage Kidney Failure at baseline, there were
1,266 incident cases of End Stage Kidney Failure giving an
overall incidence rate of 3.03 per 10,000 person years. For
men, there were 1,534 cases of End Stage Kidney Failure
arising from 4,193,578 person years giving a crude inci-
dence rate of 3.66 per 10,000 person years.
The incidence rates for both outcomes in the THIN val-
idation cohort were very similar to that for both QRe-
search® cohorts.
Model Development
Moderate-severe CKD
Table 4 shows the variables included in the final algo-
rithm for moderate-severe CKD with the hazard ratios,
fractional polynomial terms for the continuous variables
and the associated interaction terms. The highest risks of
moderate-severe CKD occurred with Type 1 diabetes
(adjusted hazard ratio 12.30, 95% CI 10.3 to 14.6 for men
and 8.21, 95% CI 6.74 to 9.99 for women). The adjusted
hazard ratios were lower for Type 2 diabetes (6.07, 95% CI
5.61 to 6.57 for men and 4.50, 95% CI 4.14 to 4.89 for 
Table 1: Characteristics of patients aged 35-74 years free of CKD at 
baseline in the QResearch derivation and the THIN validation 
cohort. 
QResearch
derivation cohort
(n = 1,574,749)
THIN
Validation cohort
(n = 1,581,745)
Women 775,091 (49.22) 784005 (49.57)
Mean age(SD) 47.3 (11.1) 49 (11.1)
Mean Townsend 
deprivation score (SD)
-0.5 (3.4) -0.7 (3.1)
Ethnic group
white/not recorded 1,511,028 (95.95) 1,548,749 (97.91)
Indian 12,360 (0.78) 8,313 (0.53)
Pakistani 6,582 (0.42) 2,370 (0.15)
Bangladeshi 2,671 (0.17) 797 (0.05)
Other Asian 5,239 (0.33) 3,652 (0.23)
Black Caribbean 9,596 (0.61) 4,131 (0.26)
Black African 10,535 (0.67) 5,224 (0.33)
Chinese 2,819 (0.18) 1,279 (0.08)
Other 13,919 (0.88) 7,230 (0.46)
Smoking status
non smoker 804,831 (51.11) 641,929 (40.58)
ex smoker 286,731 (18.21) 236,820 (14.97)
light smoker 101,273 (6.43) 96,347 (6.09)
moderate smoker 124,246 (7.89) 153,262 (9.69)
heavy smoker 100,891 (6.41) 150,036 (9.49)
smoker amount not 
recorded
42,309 (2.69) 204,564 (12.93)
smoking not 
recorded
114,468 (7.27) 98,787 (6.25)
Clinical conditions
Type 1 diabetes 4,441 (0.28) 4,940 (0.31)
Type 2 diabetes 49,179 (3.12) 49,877 (3.15)
Cardiovascular 
disease
70,865 (4.50) 80,977 (5.12)
Congestive cardiac 
failure
7,366 (0.47) 8,073 (0.51)
Peripheral vascular 
disease
16,015 (1.02) 20,066 (1.27)
Treated 
hypertension
156,506 (9.94) 142,192 (8.99)
Rheumatoid 
arthritis
11,933 (0.76) 14,137 (0.89)
Systemic lupus 
erythematosis
1,094 (0.07) 1,103 (0.07)
Kidney Stones 10,674 (0.68) 12,115 (0.77)
Current use of 
NSAIDS
425,775 (27.04) 387,087 (24.47)
Family history of 
kidney disease
719 (0.05) 1,097 (0.07)
Clinical values
systolic blood 
pressure recorded
1,415,467 (89.89) 1,437,893 (90.91)
mean systolic 
blood pressure (SD)
133.1 (19.5) 133.6 (19.6)
body mass index 
recorded
1,241,158 (78.82) 1,253,686 (79.26)
mean body mass 
index (SD)
26.7 (4.7) 26.8 (4.7)
creatinine recorded 
ever
880,627 (55.92) 863,948 (54.62)
mean Creatinine 
(SD)
86.2 (15.9) 86.3 (16.3)
creatinine recorded 
prior to baseline
331,018 (21.02) 217,814 (13.77)
complete data (for 
SBP, BMI & 
smoking)
1,214,906 (77.15) 1,226,974 (77.57)
Values are numbers (%).
Data for the QResearch validation cohort is not shown but is available 
from the authors.
Table 1: Characteristics of patients aged 35-74 years free of CKD at 
baseline in the QResearch derivation and the THIN validation 
cohort.  (Continued)Hippisley-Cox and Coupland BMC Family Practice 2010, 11:49
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Pakistani patients had the highest risks which were
almost twice those in the "White or ethnicity not
recorded" group. The adjusted hazard ratios were 2.00
(95% CI 1.70 to 2.35) for Pakistani men and 1.55 (95% CI
1.32 to 1.81) for Pakistani women. Lowest risks were
observed among black Caribbean women (adjusted haz-
ard ratio 0.48, 95% CI 0.41 to 0.57) and Black African
women (adjusted hazard ratio 0.56, 95% CI 0.43 to 0.74).
Smokers, men and women from deprived areas, those
with cardiovascular disease, congestive cardiac failure,
peripheral vascular disease, NSAID use, family history of
kidney disease, treated hypertension and rheumatoid
arthritis also had increased risks compared with patients
without those factors. Kidney stones and systemic lupus
erythematosis were significant predictors in women but
not in men. Prostatic hypertrophy was not an indepen-
dent risk factor for men so was not included in the final
model.
End Stage Kidney Failure
Table 5 shows the hazard ratios for End Stage Kidney
Failure. Patients with type 1 and type 2 diabetes, conges-
tive cardiac failure, treated hypertension and those with a
family history of kidney disease all had more than twice
the risk of End Stage Kidney Failure compared with
patients without these factors. Kidney stones and sys-
temic lupus erythematosis were significant predictors in
women but not in men.
Other predictors in both men and women included
deprivation, smoking, cardiovascular disease, rheumatoid
arthritis and peripheral vascular disease. The increased
risks associated with these factors were less marked than
the factors above. NSAID use was not significant in men
or women. Prostatic hypertrophy was not an independent
risk factor for men so was not included in the final model.
Validation of the risk prediction algorithms
For the THIN cohort, the model to predict moderate-
severe CKD explained 56.38% of the total variation in
women and 57.49% for men (Table 6). The D statistic val-
ues were high indicating good discrimination with values
of 2.33 for women and 2.38 for men. The ROC statistic
was also high with values of 0.875 for women and 0.876
for men.
The D statistic, R2 statistic and ROC statistics had mar-
ginally higher values for the moderate-severe CKD model
compared with the End Stage Kidney Failure model sug-
gesting marginally better performance for the moderate-
severe CKD model in both men and women (Table 6).
Both algorithms were well calibrated in the THIN
cohort as shown by the close correspondence between
observed and predicted values in the calibration graphs
across tenths of predicted risk both for moderate-severe
CKD (Figure 1) and End Stage Kidney Failure (Figure 2).
The corresponding results for all validation statistics
for both models in men and women in the QResearch val-
idation cohort were very similar as can be seen in Table 6.
Table 2: Incidence rates of moderate-severe CKD per 10,000 person years (95% CI) in the QResearch derivation cohort and THIN 
validation cohort
QResearch
derivation cohort
THIN
validation cohort
Women Total 58.46 (57.72 to 59.21) 64.61 (63.81 to 65.43)
35-39 yrs 5.27 (4.76 to 5.83) 5.57 (5.02 to 6.17)
40-44 yrs 7.11 (6.49 to 7.79) 9.34 (8.59 to 10.15)
45-49 yrs 14.09 (13.13 to 15.11) 14.62 (13.62 to 15.70)
50-54 yrs 24.35 (23.07 to 25.70) 26.61 (25.23 to 28.07)
55-59 yrs 43.76 (42.02 to 45.56) 47.98 (46.11 to 49.93)
60-64 yrs 89.55 (86.70 to 92.50) 99.94 (96.83 to 103.14)
65-69 yrs 167.61 (163.41 to 171.92) 182.76 (178.22 to 187.43)
70-74 yrs 291.44 (285.44 to 297.57) 315.58 (309.13 to 322.16)
Men Total 42.05 (41.43 to 42.68) 49.81 (49.10 to 50.52)
35-39 yrs 4.61 (4.15 to 5.12) 6.26 (5.69 to 6.89)
40-44 yrs 6.82 (6.23 to 7.47) 9.92 (9.17 to 10.74)
45-49 yrs 11.7 (10.85 to 12.61) 15.72 (14.70 to 16.82)
50-54 yrs 18.82 (17.71 to 19.99) 24.06 (22.76 to 25.44)
55-59 yrs 33.47 (31.96 to 35.04) 40.93 (39.21 to 42.73)
60-64 yrs 65.64 (63.19 to 68.19) 75.49 (72.77 to 78.31)
65-69 yrs 129.01 (125.23 to 132.90) 150.21 (145.98 to 154.56)
70-74 yrs 224.47 (218.85 to 230.24) 248.59 (242.41 to 254.93)Hippisley-Cox and Coupland BMC Family Practice 2010, 11:49
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Clinical assessment tools
Individual clinical assessment
Figure 3 shows 8 clinical case histories using the model to
predict moderate-severe CKD and end stage kidney fail-
ure using the web calculator http://www.qkidney.org
Population assessment using the risk stratification tool
The QKidney® Scores can also be used to risk stratify an
entire population aged 35-74 years to identify patients at
highest risk for more proactive intervention as part of the
systematic Vascular Risk Assessment Programme cur-
rently underway in the UK[8]. Since there are no estab-
lished thresholds for risk of CKD comparable with the
20% threshold for cardiovascular disease[28-30], we
defined these based on the distribution of the models
within the QResearch validation cohort (which were
extremely similar to those also found in the THIN analy-
sis)
For example, the cut off for the top tenth for risk of
moderate-severe CKD gives a 5 year risk threshold of
5.46% in men and 8.01% in women. This top tenth con-
tained 58.01% of all men in the QResearch validation
cohort who developed moderate-severe CKD over the 5
year period from baseline and 55.68% of women.
For End Stage Kidney Failure, the cut off for the top
tenth gives a 5 year risk threshold of 0.49% in men and
0.36% in women. This top tenth contained 55.93% of all
men in the QResearch validation cohort who developed
End Stage Kidney Failure over the 5 year period from
baseline and 55.44% of women.
Applying the QResearch age/sex incidence rates of
moderate-severe CKD to the estimated population of
England and Wales aged 35-74 for 2007, we estimate
there will be about 807,400 new cases of moderate-severe
CKD in the next 5 years. This is a conservative estimate
since the population is likely to age over the next 5 years.
Using the moderate-severe CKD algorithm to identify the
10% of patients with the highest risk would be expected
to identify approximately 457,700 of the patients who
develop moderate or severe CKD over the next 5 years.
Assuming an intervention with 10% effectiveness at
reducing risk, then approximately 45,770 cases of CKD
could be prevented in England and Wales over the next 5
years by targeting the intervention at those at greatest
risk.
Applying the QResearch age/sex incidence rates of End
Stage Kidney Failure to the estimated population of Eng-
land and Wales aged 35-74 for 2007, we estimate there
will be about 46,500 new cases of End Stage Kidney Fail-
ure in the next 5 years. Using the End Stage Kidney Fail-
ure algorithm to identify the 10% of patients with the
highest risk, would identify approximately 25,900 of these
patients. Assuming an intervention with 10% effective-
ness at reducing risk, then approximately 2,590 cases of
End Stage Kidney Failure could be prevented in England
and Wales over the next 5 years by targeting the interven-
tion at those at greatest risk.
Discussion
Summary of Main Findings
We have derived and validated two new algorithms
designed to predict an individual's 5 year risk of being
diagnosed with (a) moderate-severe CKD or (b) End
Stage Kidney Failure. Both algorithms are based on fac-
tors which the user is likely to know and which are likely
to be recorded within the patient's electronic health
record. The algorithms do not require a laboratory mea-
surement. They are therefore suitable for situations
where this information is not readily available and can be
used as part of a Vascular Risk Assessment to flag up
those patients who need referral to the GP for a more
detailed assessment. They can also be used to inform
patients about their level of absolute risk to help them
make an informed choice regarding the need for further
assessment or intervention.
At population level, these algorithms can be used to
"risk stratify" the entire population to systematically iden-
tify those patients who need investigation (e.g. creatinine
Table 3: Incidence rates of End Stage Kidney Failure per 10,000 
person years (95% CI) in the QResearch derivation cohort and 
THIN validation cohort
QResearch
derivation cohort
THIN
validation cohort
Women total 3.03 (2.87 to 3.20) 3.03 (2.86 to 3.21)
35-39 yrs 0.83 (0.65 to 1.07) 0.70 (0.52 to 0.93)
40-44 yrs 0.95 (0.74 to 1.22) 1.18 (0.93 to 1.49)
45-49 yrs 1.40 (1.12 to 1.74) 1.41 (1.13 to 1.78)
50-54 yrs 1.64 (1.33 to 2.02) 1.95 (1.61 to 2.38)
55-59 yrs 2.56 (2.17 to 3.02) 2.99 (2.55 to 3.50)
60-64 yrs 4.45 (3.86 to 5.13) 4.29 (3.69 to 4.98)
65-69 yrs 6.44 (5.68 to 7.30) 7.00 (6.18 to 7.93)
70-74 yrs 11.6 (10.52 to 12.79) 9.59 (8.58 to 10.72)
Men Total 3.66 (3.48 to 3.85) 3.88 (3.69 to 4.08)
35-39 yrs 1.01 (0.80 to 1.26) 1.19 (0.95 to 1.48)
40-44 yrs 1.18 (0.95 to 1.47) 1.55 (1.27 to 1.89)
45-49 yrs 1.51 (1.22 to 1.86) 1.98 (1.64 to 2.39)
50-54 yrs 2.30 (1.94 to 2.73) 2.38 (2.00 to 2.84)
55-59 yrs 3.64 (3.17 to 4.18) 3.58 (3.10 to 4.14)
60-64 yrs 5.09 (4.44 to 5.82) 5.22 (4.55 to 5.99)
65-69 yrs 9.48 (8.52 to 10.55) 9.71 (8.70 to 10.83)
70-74 yrs 14.24 (12.93 to 15.68) 14.36 (12.98 to 15.88)Hippisley-Cox and Coupland BMC Family Practice 2010, 11:49
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Table 4: Adjusted hazard ratios for risk of moderate-severe CKD using the QResearch derivation cohort
Adjusted hazard ratio
(95%CI)
women
Adjusted hazard ratio
(95%CI)
men
Ethnic group
White or ethnicity not recorded
Indian§ 1.03 (.896 to 1.18) 1.16 (1.01 to 1.34)
Pakistani§ 1.55 (1.32 to 1.81) 2.00 (1.70 to 2.35)
Bangladeshi§ 1.50 (1.14 to 1.95) 1.35 (1.03 to 1.78)
Other Asian§ 1.16 (0.89 to 1.52) 1.44 (1.09 to 1.90)
Black Caribbean§ 0.48 (0.41 to 0.57) 0.83 (0.69 to 0.99)
Black African§ 0.56 (0.43 to 0.74) 1.17 (0.90 to 1.54)
Chinese§ 1.13 (0.77 to 1.65) 1.36 (0.89 to 2.07)
Other ethnic group§ 1.23 (1.07 to 1.40) 1.33 (1.13 to 1.57)
Co-morbidity
Type 1 diabetes ± 8.21 (6.74 to 9.99) 12.3 (10.3 to 14.6)
Type 2 diabetes ± 4.50 (4.14 to 4.89) 6.07 (5.61 to 6.57)
Cardiovascular disease ± 1.37 (1.32 to 1.42) 1.40 (1.34 to 1.45)
Congestive cardiac failure ± 2.27 (2.11 to 2.45) 2.84 (2.66 to 3.03)
Peripheral vascular disease 1.35 (1.25 to 1.46) 1.47 (1.37 to 1.57)
Treated hypertension ± 2.49 (2.33 to 2.66) 2.78 (2.59 to 2.99)
NSAID use ± 1.30 (1.27 to 1.34) 1.29 (1.25 to 1.33)
Family history of kidney disease ± 2.13 (1.39 to 3.27) 3.58 (2.19 to 5.84)
Rheumatoid arthritis ± 1.62 (1.51 to 1.75) 1.48 (1.30 to 1.67)
Systemic lupus erythematosis ± 2.40 (1.92 to 3.00) n/a*
History of kidney stones ± 1.27 (1.11 to 1.46) n/a*
Smoking status
Non smoker 1.00 1.00
Ex smoker ± 1.19 (1.15 to 1.23) 1.13 (1.09 to 1.17)
Light smoker ± 1.30 (1.23 to 1.38) 1.15 (1.08 to 1.22)
Moderate smoker ± 1.27 (1.21 to 1.34) 1.24 (1.16 to 1.32)
Heavy smoker ± 1.43 (1.34 to 1.52) 1.25 (1.16 to 1.34)
Townsend score (per 5 unit increase) 1.16 (1.14 to 1.18) 1.10 (1.08 to 1.19)
± compared with patients without the condition/medication at baseline.
§ Compared with patients in the white/not recorded group
*n/a as not included in the final model
Models also included fractional polynomial terms for age, body mass index and systolic blood pressure. The fractional polynomial terms were as 
follows:
Both sexes: age terms were (age/10)3 and (age/10)3*ln(age/10)
Both sexes: bmi terms were (bmi/10)-2 and (bmi/10)-2*ln(bmi/10)
Women: sbp terms were (sbp/100)-2 and (sbp/100)-2*ln(sbp/100)
Men: sbp terms were (sbp/100)-2 and (sbp/100)-0.5
The model also included interactions between the age terms and type 1 diabetes, type 2 diabetes and treated hypertensionHippisley-Cox and Coupland BMC Family Practice 2010, 11:49
http://www.biomedcentral.com/1471-2296/11/49
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Table 5: Adjusted hazard ratios for risk of End Stage Kidney Failure using the QResearch derivation cohort
Adjusted hazard ratio
(95%CI)
women
Adjusted hazard ratio
(95%CI)
men
Ethnic group
White or ethnicity not recorded
Indian§ 1.16 (.691 to 1.94) 1.37 (0.90 to 2.07)
Pakistani§ 2.48 (1.54 to 3.98) 1.83 (1.05 to 3.18)
Bangladeshi§ 0.93 (0.30 to 2.90) 1.22 (0.54 to 2.75)
Other Asian§ 3.07 (1.64 to 5.76) 2.39 (1.19 to 4.81)
Black Caribbean§ 1.01 (0.64 to 1.61) 1.56 (1.01 to 2.43)
Black African§ 1.63 (0.89 to 2.99) 1.87 (0.99 to 3.51)
Chinese§ 3.50 (1.56 to 7.84) insufficient numbers
Other ethnic group§ 1.36 (0.82 to 2.23) 0.96 (0.52 to 1.79)
Co-morbidity
Type 1 diabetes ± 22.3 (14.7 to 33.8) 11.3 (7.59 to 16.9)
Type 2 diabetes ± 4.68 (3.58 to 6.11) 2.79 (2.17 to 3.58)
Cardiovascular disease ± 1.35 (1.14 to 1.58) 1.34 (1.18 to 1.53)
Congestive cardiac failure ± 4.45 (3.55 to 5.57) 4.02 (3.33 to 4.86)
Peripheral vascular disease 1.7 (1.3 to 2.23) 1.98 (1.62 to 2.42)
Treated hypertension ± 4.8 (3.96 to 5.82) 6.77 (5.71 to 8.02)
Family history of kidney disease ± 6.41 (2.4 to 17.1) 9.68 (4.01 to 23.4)
Rheumatoid arthritis ± 1.52 (1.1 to 2.1) 1.53 (1.01 to 2.34)
Systemic lupus erythematosis ± 4.69 (2.63 to 8.35) n/a
History of kidney stones ± 2.07 (1.34 to 3.19) n/a
Smoking status
Non smoker
Ex smoker ± 1.22 (1.06 to 1.40) 1.16 (1.03 to 1.3)
Light smoker ± 1.45 (1.13 to 1.85) 1.17 (0.98 to 1.41)
Moderate smoker ± 1.08 (0.85 to 1.38) 1.33 (1.09 to 1.63)
Heavy smoker ± 1.43 (1.11 to 1.83) 1.09 (.858 to 1.38)
Townsend score (per 5 unit increase) 1.23 (1.13 to 1.34) 1.10 (1.02 to 1.19)
± compared with patients without the condition/medication at baseline.
§ Compared with patients in the white/not recorded group
Models also included fractional polynomial terms for age, body mass index and systolic blood pressure. The fractional polynomial terms were as 
follows:
Both sexes: age terms were (age/10)3 and (age/10)3*ln(age/10)
Both sexes: bmi terms were (bmi/10)-2 and (bmi/10)-2*ln(bmi/10)
Women: sbp terms were (sbp/100)-2 and (sbp/100)-2*ln(sbp/100)
Men: sbp terms were (sbp/100)-2 and (sbp/100)-0.5
The model also included interactions between the age terms and type 1 diabetes, type 2 diabetes and treated hypertensionHippisley-Cox and Coupland BMC Family Practice 2010, 11:49
http://www.biomedcentral.com/1471-2296/11/49
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test) or further assessment or regular monitoring. This
could be achieved by automatically applying these algo-
rithms to the computerised medical records of all
patients aged 35-74 registered with a practice. This meets
a core requirement of the NHS Programme for IT,
namely to "calculate the risk of the renal function deterio-
rating, taking all recorded risk factors into account, and
the recalculation of risk on a regular basis to take account
of changes as a result of ageing or whenever more patient
information becomes available (e.g. test results)" (per-
sonal communication).
Once identified, high risk patients can then avoid neph-
rotoxic drugs (such as NSAIDs), have more energetic
treatment to lower blood pressure, reduce blood pressure
targets or have more frequent follow up of kidney func-
tion to allow earlier referral to secondary care services.
Further research is required to identify the effectiveness
of these interventions in a high risk population.
Comparison with other studies
To our knowledge, these are the first algorithms to pre-
dict both the risk of moderate-severe CKD and the risk of
End Stage Kidney Failure in UK primary care. They
improve on a recently described algorithm to predict
CKD derived using 9,470 participants from the American
ARIC/CHS cohorts [31]. Both studies used similar statis-
tical methods for the derivation and validation of the
algorithms. In the ARIC/CHS study, the outcome
included patients with the more mild Stage 3a disease
which has less certain prognostic significance. Our algo-
rithms include additional known risk factors such as fam-
ily history of kidney disease, use of NSAIDS, kidney
stones, rheumatoid arthritis, systemic lupus erythemato-
sis, body mass index and smoking status. They also
include more detailed variables for ethnic group, interac-
tions with age and distinguish between type 1 and type 2
diabetes, which have markedly different risks. Our ROC
values were all in excess of 0.82 which is substantially bet-
ter than the ROC statistic of 0.70 reported in the ARIC/
CHS study[31].
Strengths and weaknesses
Strengths and weaknesses of our study are likely to be
similar to those discussed in detail elsewhere[10-12,14-
16]. Weaknesses, as with all observational studies,
include the potential for bias. Misclassification bias of
Table 6: Validation statistics for each models in the THIN and QResearch® validation cohorts
moderate-severe CKD End Stage Kidney Failure
Women THIN cohort
R2 statistic (%) 56.19 (55.67 to 56.70) 54.02 (51.67 to 56.37)
D statistic 2.32 (2.30 to 2.34) 2.22 (2.11 to 2.32)
ROC statistic 0.875 (0.872 to 0.877) 0.818 (0.803 to 0.833)
QResearch cohort
R2 statistic (%) 56.45 (55.40 to 57.50) 55.39 (0.52.59 to 58.18)
D statistic 2.33 (2.28 to 2.40) 2.28 (2.15 to 2.41)
ROC statistic 0.877 (0.873 to 0.880) 0.843 (0.825 to 0.860)
Men THIN cohort
R2 statistic (%) 57.41 (54.56 to 60.27) 52.86 (50.55 to 55.17)
D statistic 2.38 (2.24 to 2.51) 2.17 (2.07 to 2.27)
ROC statistic 0.875 (0.873 to 0.878) 0.839 (0.827 to 0.850)
QResearch cohort
R2 statistic (%) 58.29 (55.31 to 61.26) 56.65 (53.94 to 59.35)
D statistic 2.42 (2.28 to 2.56) 2.34 (2.21 to 2.47)
ROC statistic 0.878 (0.874 to 0.882) 0.846 (0.829 to 0.862)
Notes on understanding validation statistics:
R2 statistic shows explained variation - higher values indicate more variation is explained
ROC statistic is a measure of discrimination - higher values indicate better discrimination
D statistic is a measure of discrimination - higher values indicate better discrimination and an increase of 0.1 or more over other risk prediction 
models is a good marker of improved prognostic separationHippisley-Cox and Coupland BMC Family Practice 2010, 11:49
http://www.biomedcentral.com/1471-2296/11/49
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outcome or predictor variables could have occurred,
which, if non-differential would tend to bias the hazard
ratios towards one and reduce discrimination. However,
it is probable that patients with established risk factors
such as diabetes would be more likely to have blood or
urine tests and this could have the effect of inflating haz-
ard ratios associated with these risk factors. Nonetheless,
our hazard ratios for the risk factors in the model apart
from diabetes, are generally of a similar magnitude to
those found in other similar studies which tested for
chronic kidney disease in the entire study cohort[31]. In
addition, the assessment and recording of these factors in
clinical practice is becoming increasingly routine and
complete, so limiting the effect of this potential bias.
Whilst the outcomes were not adjudicated by a panel of
clinicians, we think it unlikely that more than a small
number of patients will have been misclassified as having
the outcomes since the definitions are based on objective
measurements or major operations or procedures. It is
possible, indeed likely, that some patients had undetected
or un-recorded kidney disease at baseline or follow-up
since there is no systematic widespread testing of blood
or urinalysis. This is in fact part of the justification for a
systematic population based approach.
We have based the date of our outcome on the date of
first recorded evidence of moderate-severe kidney dis-
ease and of end stage kidney failure. Given the insidious
and gradual nature of decline in kidney function, it is
likely that the real onset occurred before the date of the
recorded onset. This will have tended to result in a gen-
eral under-estimation of incidence rates which in turn
would lead to an under-estimation in individualised risk
estimates. However, we think in some cases the date of
first recorded evidence may relate closely to the onset of
symptoms leading to a consultation and blood or urine
tests. Although some alternative analytical methods are
available to allow for interval censored data these tend to
make stronger assumptions than Cox regression about
the distribution of the hazard rate, and often group all
outcome dates into fixed intervals, hence potentially los-
ing precision.
Key strengths include size, representativeness due to
inclusion of entire practice populations and quality of the
database used to derive the algorithm and its ability to
generalise back into the setting where it can be applied.
The algorithms are well calibrated to the setting in which
they can be used and have good levels of discrimination.
Our study has good face validity as the vast majority of
risk factors identified in the literature or by consensus
were found to be independent predictors and hence
included in the QKidney® Scores[1,2,18]. As in other stud-
ies, we found an association between increasing levels of
deprivation and risk of CKD [3] as well as confirming eth-
nic differences [19]. The inclusion of ethnic group and
deprivation within the risk prediction scores should help
avoid widening inequalities which can occur at the start
of major new public health initiatives[32]. Lastly, we have
validated each algorithm in an external set of practices
contributing to the THIN database and demonstrated
comparable performance with the validation cohort from
the QResearch® database. We found very close similarities
for a wide range of population characteristics between
the THIN and QResearch® cohorts. This helps validate
both databases and is reassuring regarding the likely gen-
eralisability of results from research using either database
to the rest of the UK.
Figure 1 Predicted and observed risks of moderate-severe CKD 
by model tenth in the THIN validation cohort.
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Figure 2 Predicted and observed risks of End Stage Kidney Fail-
ure by model tenth in the THIN validation cohort.
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Figure 3 Clinical case histories for individual patients using the Web Calculator . http://www.qkidney.org.
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Conclusions
We have developed and validated two new risk prediction
algorithms designed to predict risk of moderate-severe
CKD and End Stage Kidney Failure in primary care which
have the potential to identify high risk patients who
might benefit from more detailed assessment, closer
monitoring or interventions to reduce their risk. Further
research is required to verify these findings as well as to
identify the effectiveness of using this approach with
appropriate interventions in a high risk population.
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